Trans women have worse cardiovascular biomarker profiles than cisgender men independent of hormone use and HIV serostatus.
1-Alkyl-2-acetylglycerophosphocholine Esterase
Adult
Biomarkers
Cardiovascular Diseases
/ epidemiology
Cohort Studies
Endothelins
Female
HIV Infections
/ complications
Hormones
Humans
Inflammation
Interleukin-6
Interleukin-8
Lipopolysaccharide Receptors
Lipoproteins, LDL
Male
Middle Aged
P-Selectin
Plasminogen Activator Inhibitor 1
Receptor for Advanced Glycation End Products
von Willebrand Factor
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
12
8
2022
medline:
1
10
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Feminizing hormonal therapy (FHT) and HIV potentially alter cardiovascular disease (CVD) risk in transgender women (TW). TW were enrolled in Los Angeles, California and Houston, Texas and frequency-matched to Multicenter AIDS Cohort Study cisgender men (CM) on age, race, substance use, and abacavir use. Biomarkers of CVD risk and inflammation were assessed via ELISA. Wilcoxon rank sum and Fisher's exact tests compared TW and CM. Multivariable linear regression assessed factors associated with biomarker concentrations. TW (HIV+ n = 75, HIV- n = 47) and CM (HIV+ n = 40, HIV- n = 40) had mean age 43-45 years; TW/CM were 90%/91% non-Hispanic Black, Hispanic, or Multiracial, 26%/53% obese, and 34%/24% current smokers; 67% of TW were on FHT. Among people with HIV (PWH), TW had higher median extracellular newly-identified receptor for advanced glycation end-products (EN-RAGE), lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), soluble tumor necrosis factor receptor type (sTNFR) I/II, interleukin (IL)-8 and plasminogen activator inhibitor (PAI)-1, but lower soluble CD14, von Willebrand factor (vWF) and endothelin (ET)-1 levels than CM. Findings were similar for participants without HIV (all P < 0.05). In multivariable analysis, TW had higher EN-RAGE, IL-6, IL-8, P selectin, PAI-1, oxLDL and sTNFRI/II concentrations, and lower vWF, independent of HIV serostatus and current FHT use. Both being a TW and a PWH were associated with lower ET-1. Compared to matched cisgender men, trans women have altered profiles of biomarkers associated with systemic inflammation and CVD. Further work is needed to decipher the contributions of FHT to CVD risk in TW with HIV.
Sections du résumé
BACKGROUND
Feminizing hormonal therapy (FHT) and HIV potentially alter cardiovascular disease (CVD) risk in transgender women (TW).
METHODS
TW were enrolled in Los Angeles, California and Houston, Texas and frequency-matched to Multicenter AIDS Cohort Study cisgender men (CM) on age, race, substance use, and abacavir use. Biomarkers of CVD risk and inflammation were assessed via ELISA. Wilcoxon rank sum and Fisher's exact tests compared TW and CM. Multivariable linear regression assessed factors associated with biomarker concentrations.
RESULTS
TW (HIV+ n = 75, HIV- n = 47) and CM (HIV+ n = 40, HIV- n = 40) had mean age 43-45 years; TW/CM were 90%/91% non-Hispanic Black, Hispanic, or Multiracial, 26%/53% obese, and 34%/24% current smokers; 67% of TW were on FHT. Among people with HIV (PWH), TW had higher median extracellular newly-identified receptor for advanced glycation end-products (EN-RAGE), lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), soluble tumor necrosis factor receptor type (sTNFR) I/II, interleukin (IL)-8 and plasminogen activator inhibitor (PAI)-1, but lower soluble CD14, von Willebrand factor (vWF) and endothelin (ET)-1 levels than CM. Findings were similar for participants without HIV (all P < 0.05). In multivariable analysis, TW had higher EN-RAGE, IL-6, IL-8, P selectin, PAI-1, oxLDL and sTNFRI/II concentrations, and lower vWF, independent of HIV serostatus and current FHT use. Both being a TW and a PWH were associated with lower ET-1.
CONCLUSIONS
Compared to matched cisgender men, trans women have altered profiles of biomarkers associated with systemic inflammation and CVD. Further work is needed to decipher the contributions of FHT to CVD risk in TW with HIV.
Identifiants
pubmed: 35950945
doi: 10.1097/QAD.0000000000003346
pii: 00002030-202211010-00007
pmc: PMC9529791
mid: NIHMS1826160
doi:
Substances chimiques
Biomarkers
0
Endothelins
0
Hormones
0
Interleukin-6
0
Interleukin-8
0
Lipopolysaccharide Receptors
0
Lipoproteins, LDL
0
P-Selectin
0
Plasminogen Activator Inhibitor 1
0
Receptor for Advanced Glycation End Products
0
von Willebrand Factor
0
1-Alkyl-2-acetylglycerophosphocholine Esterase
EC 3.1.1.47
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1801-1809Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL146245
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146208
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI120834
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146192
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146242
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI110532
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146194
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146241
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027767
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146333
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146205
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH116867
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI073961
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK126042
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146201
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146193
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI141014
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146204
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146202
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000004
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146240
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL146203
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003098
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case–control study . Eur J Endocrinol 2013; 169:471–478.
Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones . Eur J Endocrinol 2011; 164:635–642.
Dhejne C, Lichtenstein P, Boman M, Johansson AL, Langstrom N, Landen M. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden . PLoS One 2011; 6:e16885.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review . JAMA 2002; 288:872–881.
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Lancet 1995; 346:1575–1582.
Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis . Eur Heart J 2008; 29:2031–2041.
Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis . JAMA 2000; 284:72–78.
Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception . N Engl J Med 2012; 366:2257–2266.
Masia M, Padilla S, Alvarez D, Lopez JC, Santos I, Soriano V, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy . AIDS 2013; 27:181–189.
Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study . HIV Med 2012; 14:195–207.
Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients . Clin Infect Dis 2012; 55:1228–1235.
Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals . J Acquir Immune Defic Syndr 2003; 33:506–512.
Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, et al. Increased cardiovascular disease risk indices in HIV-infected women . J Acquir Immune Defic Syndr 2005; 39:44–54.
Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, Nappa S, et al. Human immunodeficiency virus per se exerts atherogenic effects . Atherosclerosis 2009; 204:586–589.
Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in patients with HIV . Lancet Diabetes Endocrinol 2016; 4:598–610.
Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis . Circulation 2018; 138:1100–1112.
Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management . Nat Rev Cardiol 2019; 16:745–759.
Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association . Circulation 2019; 140:e98–e124.
Funderburg NT, Zidar DA, Shive C, Lioi A, Mudd J, Musselwhite LW, et al. Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome . Blood 2012; 120:4599–4608.
Anzinger JJ, Angelovich BT, Crowe TA, Palmer CS SM. Monocytes as regulators of inflammation and HIV-related comorbidities during cART . J Immunol Res 2014; 2014:569819.
Liang H, Xie Z, Shen T. Monocyte activation and cardiovascular disease in HIV infection . Cell Mol Immunol 2017; 14:960–962.
Teer E, Joseph DE, Glashoff RH, Faadiel Essop M. Monocyte/macrophage-mediated innate immunity in HIV-1 infection: from early response to late dysregulation and links to cardiovascular diseases onset . Virol Sin 2021; 36:565–576.
Funderburg NT, Mayne E, Sieg SF, Asaad R, Jiang W, Kalinowska M, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation . Blood 2010; 115:161–167.
Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, et al. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation . J Am Heart Assoc 2013; 2:e000264.
Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection . Thromb Res 2014; 133: (Suppl 1): S21–S24.
CIA. HIV/AIDS-adult prevalence rate gay, bisexual and transgender (LGBT) . 2020. Available at. www.cia.gov .
Lee JG, Griffin GK, Melvin CL. Tobacco use among sexual minorities in the USA, 1987 to May 2007: a systematic review . Tob Control 2009; 18:275–282.
Berger I, Mooney-Somers J. Smoking cessation programs for lesbian, gay, bisexual, transgender, and intersex people: a content-based systematic review . Nicotine Tob Res 2017; 19:1408–1417.
Buchting FO, Emory KT, Scout, Kim Y, Fagan P, Vera LE, et al. Transgender use of cigarettes, cigars, and E-cigarettes in a national study . Am J Prev Med 2017; 53:e1–e7.
Office on Smoking and Health NCfCDPaHP, Centers for Disease Control and Prevention. Lesbian, gay, bisexual, and transgender (LGBT) people . 2022. Available at www.cdc.gov/tobacco/campaign/tips/groups/lgbt.html .
Malhotra A, Kort S, Lauther T, Mann N, Skopicki HA, Parikh PB. Prevalence and predictors of cardiovascular disease and risk factors in transgender persons in the United States . Crit Pathw Cardiol 2022; 21:42–46.
Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants . Am J Epidemiol 1987; 126:310–318.
Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population . Circ Cardiovasc Qual Outcomes 2019; 12:e005597.
Testa RJ, Habarth J, Peta J, Balsam K, Bockting W. Development of the gender minority stress and resilience measure in psychology of sexual orientation and gender diversity . Psychol Sexual Orientat Gender Diversity 2015; 2:65–77.
Streed CG, Beach LB, Caceres BA, Dowshen NL, Moreau KL, Mukherjee M, et al. Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association . Circulation 2021; 144:e136–e148.
Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides . Cell 1999; 97:889–901.
Foell D, Wittkowski H, Kessel C, Lüken A, Weinhage T, Varga G, et al. Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4 . Am J Respir Crit Care Med 2013; 187:1324–1334.
Ligthart S, Sedaghat S, Ikram MA, Hofman A, Franco OH, Dehghan A. EN-RAGE: a novel inflammatory marker for incident coronary heart disease . Arterioscler Thromb Vasc Biol 2014; 34:2695–2699.
Varghese DS, Ali BR. Pathological crosstalk between oxidized LDL and ER stress in human diseases: a comprehensive review . Front Cell Dev Biol 2021; 9:674103.
Morrow GB, Whyte CS, Mutch NJ. A serpin with a finger in many PAIs: PAI-1's central function in thromboinflammation and cardiovascular disease . Front Cardiovasc Med 2021; 8:653655.
Farokhzadian J, Mangolian Shahrbabaki P, Bagheri V. S100A12-CD36 axis: a novel player in the pathogenesis of atherosclerosis? . Cytokine 2019; 122:154104.
Kang S, Tanaka T, Inoue H, Ono C, Hashimoto S, Kioi Y, et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome . Proc Natl Acad Sci USA 2020; 117:22351–22356.
Lubrano V, Gabriele M, Puntoni MR, Longo V, Pucci L. Relationship among IL-6, LDL cholesterol and lipid peroxidation . Cell Mol Biol Lett 2015; 20:310–322.
Hasegawa T, Kosaki A, Kimura T, Matsubara H, Mori Y, Okigaki M, et al. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages . Atherosclerosis 2003; 171:211–218.
Larsen A, Bronstein IB, Dahl O, Wentzel-Larsen T, Kristoffersen EK, Fagerhol MK. Quantification of S100A12 (EN-RAGE) in blood varies with sampling method, calcium and heparin . Scand J Immunol 2007; 65:192–201.
Manolakis AC, Kapsoritakis AN, Georgoulias P, Tzavara C, Valotassiou V, Kapsoritaki A, et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome . BMC Gastroenterol 2010; 10:118.
Gohar EY, Giachini FR, Pollock DM, Tostes RC. Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases . Life Sci 2016; 159:20–29.
Looby SE, Kantor A, Burdo TH, Currier JS, Fichtenbaum CJ, Overton ET, et al. Factors associated with systemic immune activation indices in a global primary cardiovascular disease prevention cohort of people with HIV on antiretroviral therapy . Clin Infect Dis 2022; ciac166.
van Kesteren PJ, Kooistra T, Lansink M, van Kamp GJ, Asscheman H, Gooren LJ, et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning . Thromb Haemost 1998; 79:1029–1033.
de Larrañaga GF, Bocassi AR, Puga LM, Alonso BS, Benetucci JA. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment . Thromb Res 2003; 110:93–98.
Novelli S, Lecuroux C, Goujard C, Reynes J, Villemant A, Blum L, et al. Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection . EBioMedicine 2020; 62:103129.
Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern . Eur J Endocrinol 2014; 170:809–819.